Premaitha sets Asia Pacific regional hub for its IONA test in Thailand


Image: Premaitha Health

Premaitha Health has established its services regional hub in Asia Pacific as Geneplus, the distributor of Premaitha’s IONA test in Thailand, has signed an agreement to offer the test in the Center for Medical Genomics (CMG), Ramathibodi Hospital, Mahidol University, partnering with the Thailand Center of Excellence for Life Sciences (TCELS).

According to the agreement, CMG in Bangkok will act as a regional hub for non-invasive prenatal tests (NIPT), accepting samples from across Thailand and nearby countries for analysis with the IONA test. The laboratory is currently completing its training and installation phase and is expected to be operational during December.


Dr Stephen Little, CEO of Premaitha, commented:

“We are delighted to have expanded our global footprint of laboratory customers to now include Thailand and that women in the country will increasingly be able to benefit from our safe and accurate non-invasive test.

“Asia Pacific is a region in which we believe there is significant potential for non-invasive prenatal testing – to secure our first operational laboratory in Asia is an important strategic milestone.”

Prof Wasun Chantratita, Head of CMG, added:

“We have chosen the IONA test not only due to its complete CE mark validation, but also because it has a scalable, flexible workflow, reliable data analysis and interpretation as well as exceptional technical support provided alongside it. We look forward to working closely with Premaitha to build the CMG into a regional centre for high quality, fast and accurate cfDNA screening.”

“Premaitha’s IONA test was launched in 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions. Unlike traditional prenatal screening methods, the IONA test is performed on the mother’s blood sample, which contains traces of fetal DNA, and then analysed using next generation DNA sequencing technology,” Premaitha noted in its Monday press release.

The company emphasises that, due to its high level of accuracy, the IONA test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are both costly and resource intensive; and carry a small risk of miscarriage.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s